BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37665491)

  • 1. Mutant HRas Signaling and Rationale for Use of Farnesyltransferase Inhibitors in Head and Neck Squamous Cell Carcinoma.
    Wang J; Al-Majid D; Brenner JC; Smith JD
    Target Oncol; 2023 Sep; 18(5):643-655. PubMed ID: 37665491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
    Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
    Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tipifarnib as a Precision Therapy for
    Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
    Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
    Desilets A; Ho AL
    Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
    Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
    Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
    Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
    Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
    Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
    Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
    Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
    J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Harvey rat sarcoma viral oncogene homolog in head and neck cancer: how to move forward?
    Ben Yahia H; Petit FM; Saada-Bouzid E
    Curr Opin Oncol; 2023 May; 35(3):178-185. PubMed ID: 36966498
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
    JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
    Hah JH; Zhao M; Pickering CR; Frederick MJ; Andrews GA; Jasser SA; Fooshee DR; Milas ZL; Galer C; Sano D; William WN; Kim E; Heymach J; Byers LA; Papadimitrakopoulou V; Myers JN
    Head Neck; 2014 Nov; 36(11):1547-54. PubMed ID: 24123531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of photodynamic therapy on expression of HRAS, NRAS and caspase 3 genes at mRNA levels, apoptosis of head and neck squamous cell carcinoma cell line.
    Yousefi M; Koopaie M; Karimi R; Kermani FM; Kolahdooz S; Shamshiri A
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102142. PubMed ID: 33307231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
    Lee RH; Johnson DE; Grandis JR
    Cancer Res; 2023 Oct; 83(19):3162-3164. PubMed ID: 37779427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
    Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
    Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
    Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
    Martin D; Abba MC; Molinolo AA; Vitale-Cross L; Wang Z; Zaida M; Delic NC; Samuels Y; Lyons JG; Gutkind JS
    Oncotarget; 2014 Oct; 5(19):8906-23. PubMed ID: 25275298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.